The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Diabetic Retinopathy Treatment Market Research Report 2025
Synopsis
Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
The global Diabetic Retinopathy Treatment market was valued at US$ 7186.3 million in 2023 and is anticipated to reach US$ 9807 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diabetic Retinopathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Retinopathy Treatment.
Report Scope
The Diabetic Retinopathy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Retinopathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Retinopathy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
ThromboGenics
Genentech
Bayer Healthcare
Alimera Sciences
Actavis
BCN Peptides
Novartis
Ampio Pharmaceuticals
Kowa Group
Sirnaomicsorporation
Abbott Laboratories
Glycadia Pharmaceuticals
Alcon Laboratories
Parexel International
Segment by Type
Proliferative Diabetic Retinopathy (PDR)
Non-Proliferative Diabetic Retinopathy (NPDR)
Segment by Application
Ophthalmic Clinics
Ambulatory Surgical Centers
Hospitals
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Retinopathy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
The global Diabetic Retinopathy Treatment market was valued at US$ 7186.3 million in 2023 and is anticipated to reach US$ 9807 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diabetic Retinopathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Retinopathy Treatment.
Report Scope
The Diabetic Retinopathy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Retinopathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Retinopathy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
ThromboGenics
Genentech
Bayer Healthcare
Alimera Sciences
Actavis
BCN Peptides
Novartis
Ampio Pharmaceuticals
Kowa Group
Sirnaomicsorporation
Abbott Laboratories
Glycadia Pharmaceuticals
Alcon Laboratories
Parexel International
Segment by Type
Proliferative Diabetic Retinopathy (PDR)
Non-Proliferative Diabetic Retinopathy (NPDR)
Segment by Application
Ophthalmic Clinics
Ambulatory Surgical Centers
Hospitals
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Retinopathy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Retinopathy Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Proliferative Diabetic Retinopathy (PDR)
1.2.3 Non-Proliferative Diabetic Retinopathy (NPDR)
1.3 Market by Application
1.3.1 Global Diabetic Retinopathy Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Ophthalmic Clinics
1.3.3 Ambulatory Surgical Centers
1.3.4 Hospitals
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Retinopathy Treatment Market Perspective (2019-2030)
2.2 Diabetic Retinopathy Treatment Growth Trends by Region
2.2.1 Global Diabetic Retinopathy Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diabetic Retinopathy Treatment Historic Market Size by Region (2019-2024)
2.2.3 Diabetic Retinopathy Treatment Forecasted Market Size by Region (2025-2030)
2.3 Diabetic Retinopathy Treatment Market Dynamics
2.3.1 Diabetic Retinopathy Treatment Industry Trends
2.3.2 Diabetic Retinopathy Treatment Market Drivers
2.3.3 Diabetic Retinopathy Treatment Market Challenges
2.3.4 Diabetic Retinopathy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy Treatment Players by Revenue
3.1.1 Global Top Diabetic Retinopathy Treatment Players by Revenue (2019-2024)
3.1.2 Global Diabetic Retinopathy Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Diabetic Retinopathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Retinopathy Treatment Revenue
3.4 Global Diabetic Retinopathy Treatment Market Concentration Ratio
3.4.1 Global Diabetic Retinopathy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Treatment Revenue in 2023
3.5 Diabetic Retinopathy Treatment Key Players Head office and Area Served
3.6 Key Players Diabetic Retinopathy Treatment Product Solution and Service
3.7 Date of Enter into Diabetic Retinopathy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Retinopathy Treatment Breakdown Data by Type
4.1 Global Diabetic Retinopathy Treatment Historic Market Size by Type (2019-2024)
4.2 Global Diabetic Retinopathy Treatment Forecasted Market Size by Type (2025-2030)
5 Diabetic Retinopathy Treatment Breakdown Data by Application
5.1 Global Diabetic Retinopathy Treatment Historic Market Size by Application (2019-2024)
5.2 Global Diabetic Retinopathy Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diabetic Retinopathy Treatment Market Size (2019-2030)
6.2 North America Diabetic Retinopathy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diabetic Retinopathy Treatment Market Size by Country (2019-2024)
6.4 North America Diabetic Retinopathy Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Retinopathy Treatment Market Size (2019-2030)
7.2 Europe Diabetic Retinopathy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diabetic Retinopathy Treatment Market Size by Country (2019-2024)
7.4 Europe Diabetic Retinopathy Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy Treatment Market Size (2019-2030)
8.2 Asia-Pacific Diabetic Retinopathy Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diabetic Retinopathy Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Diabetic Retinopathy Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Retinopathy Treatment Market Size (2019-2030)
9.2 Latin America Diabetic Retinopathy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diabetic Retinopathy Treatment Market Size by Country (2019-2024)
9.4 Latin America Diabetic Retinopathy Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy Treatment Market Size (2019-2030)
10.2 Middle East & Africa Diabetic Retinopathy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diabetic Retinopathy Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Diabetic Retinopathy Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Detail
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Diabetic Retinopathy Treatment Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 ThromboGenics
11.2.1 ThromboGenics Company Detail
11.2.2 ThromboGenics Business Overview
11.2.3 ThromboGenics Diabetic Retinopathy Treatment Introduction
11.2.4 ThromboGenics Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.2.5 ThromboGenics Recent Development
11.3 Genentech
11.3.1 Genentech Company Detail
11.3.2 Genentech Business Overview
11.3.3 Genentech Diabetic Retinopathy Treatment Introduction
11.3.4 Genentech Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.3.5 Genentech Recent Development
11.4 Bayer Healthcare
11.4.1 Bayer Healthcare Company Detail
11.4.2 Bayer Healthcare Business Overview
11.4.3 Bayer Healthcare Diabetic Retinopathy Treatment Introduction
11.4.4 Bayer Healthcare Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.4.5 Bayer Healthcare Recent Development
11.5 Alimera Sciences
11.5.1 Alimera Sciences Company Detail
11.5.2 Alimera Sciences Business Overview
11.5.3 Alimera Sciences Diabetic Retinopathy Treatment Introduction
11.5.4 Alimera Sciences Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.5.5 Alimera Sciences Recent Development
11.6 Actavis
11.6.1 Actavis Company Detail
11.6.2 Actavis Business Overview
11.6.3 Actavis Diabetic Retinopathy Treatment Introduction
11.6.4 Actavis Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.6.5 Actavis Recent Development
11.7 BCN Peptides
11.7.1 BCN Peptides Company Detail
11.7.2 BCN Peptides Business Overview
11.7.3 BCN Peptides Diabetic Retinopathy Treatment Introduction
11.7.4 BCN Peptides Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.7.5 BCN Peptides Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Diabetic Retinopathy Treatment Introduction
11.8.4 Novartis Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Ampio Pharmaceuticals
11.9.1 Ampio Pharmaceuticals Company Detail
11.9.2 Ampio Pharmaceuticals Business Overview
11.9.3 Ampio Pharmaceuticals Diabetic Retinopathy Treatment Introduction
11.9.4 Ampio Pharmaceuticals Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.9.5 Ampio Pharmaceuticals Recent Development
11.10 Kowa Group
11.10.1 Kowa Group Company Detail
11.10.2 Kowa Group Business Overview
11.10.3 Kowa Group Diabetic Retinopathy Treatment Introduction
11.10.4 Kowa Group Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.10.5 Kowa Group Recent Development
11.11 Sirnaomicsorporation
11.11.1 Sirnaomicsorporation Company Detail
11.11.2 Sirnaomicsorporation Business Overview
11.11.3 Sirnaomicsorporation Diabetic Retinopathy Treatment Introduction
11.11.4 Sirnaomicsorporation Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.11.5 Sirnaomicsorporation Recent Development
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Detail
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Diabetic Retinopathy Treatment Introduction
11.12.4 Abbott Laboratories Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.12.5 Abbott Laboratories Recent Development
11.13 Glycadia Pharmaceuticals
11.13.1 Glycadia Pharmaceuticals Company Detail
11.13.2 Glycadia Pharmaceuticals Business Overview
11.13.3 Glycadia Pharmaceuticals Diabetic Retinopathy Treatment Introduction
11.13.4 Glycadia Pharmaceuticals Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.13.5 Glycadia Pharmaceuticals Recent Development
11.14 Alcon Laboratories
11.14.1 Alcon Laboratories Company Detail
11.14.2 Alcon Laboratories Business Overview
11.14.3 Alcon Laboratories Diabetic Retinopathy Treatment Introduction
11.14.4 Alcon Laboratories Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.14.5 Alcon Laboratories Recent Development
11.15 Parexel International
11.15.1 Parexel International Company Detail
11.15.2 Parexel International Business Overview
11.15.3 Parexel International Diabetic Retinopathy Treatment Introduction
11.15.4 Parexel International Revenue in Diabetic Retinopathy Treatment Business (2019-2024)
11.15.5 Parexel International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
